SCHEDULE: Viking Global Investors Reduces Stake in BridgeBio Pharma to 9.8%

Viking Global Investors and its affiliated entities have filed an Amendment No. 7 to their Schedule 13D, reporting a reduced beneficial ownership of 9.8% in BridgeBio Pharma, Inc. following significant net selling of shares.

Summary

• Viking Global Investors LP and its affiliated entities, including various funds and general partners, collectively report beneficial ownership of 18,602,920 shares of BridgeBio Pharma, Inc. Common Stock.
• This ownership represents 9.8% of BridgeBio Pharma's outstanding Common Stock, based on 189,880,720 shares outstanding as of April 22, 2025.
• Key individuals O. Andreas Halvorsen, David C. Ott, and Rose S. Shabet, as Executive Committee Members of Viking Global Partners LLC, also have shared beneficial ownership over the same 18,602,920 shares.
• During the past 60 days, the Reporting Persons engaged in significant net selling, disposing of approximately 3,516,644 shares while acquiring 64,189 shares, resulting in a net reduction of 3,452,455 shares.
• Notable transactions include the sale of 3,283,310 shares by Viking Global Opportunities Illiquid Investments Sub-Master LP at $44.00 per share on June 27, 2025.
• Other sales on June 27, 2025, included 155,000 shares by Viking Global Equities Master Ltd. and 61,690 shares by Viking Long Fund Master Ltd., both at $44.00 per share.
• Purchases on July 1, 2025, included 16,644 shares by Viking Global Opportunities Liquid Portfolio Sub-Master LP at $42.145, and additional buys by Viking Global Equities II LP, Viking Global Opportunities Liquid Portfolio Sub-Master LP, and Viking Long Fund Master Ltd. at a weighted average price of $42.2819.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative due to the significant net selling of shares by a major institutional investor, which reduced their overall stake in the company. While they still hold a substantial position, the reduction could be perceived as a decrease in conviction.

Positives

• Viking Global Investors and its affiliates maintain a substantial beneficial ownership stake of 9.8% in BridgeBio Pharma, indicating continued significant investment interest.
• The filing provides transparency regarding the complex ownership structure and control mechanisms within the Viking Global group.

Negatives

• The Reporting Persons engaged in significant net selling of 3,452,455 shares of BridgeBio Pharma Common Stock over the past 60 days, reducing their overall stake from approximately 11.6% to 9.8%.
• Large-scale selling by a major institutional investor like Viking Global could be interpreted negatively by the market, potentially signaling a reduction in conviction or a portfolio rebalancing away from the issuer.

Risks

• The reduction in beneficial ownership by a significant institutional investor like Viking Global could lead to decreased investor confidence or increased selling pressure on BridgeBio Pharma's stock.
• Future large-scale dispositions by the Reporting Persons could further impact the stock price and market liquidity.

Future Outlook

The document does not provide forward-looking statements or guidance from BridgeBio Pharma, Inc. or the Reporting Persons regarding the issuer's future performance or strategic direction. The filing solely details changes in beneficial ownership.

Industry Context

This filing is a routine disclosure of changes in beneficial ownership by a major institutional investor in a biotechnology company. It does not provide broader industry trends or competitive analysis, but reflects an investment decision within the pharmaceutical and biotechnology sector.

Comparison to Industry Standards

• NA

Legal Proceedings

• None of the Reporting Persons have been convicted in any criminal proceeding (excluding traffic violations or similar misdemeanors) during the last five years.
• None of the Reporting Persons were a party to a civil proceeding of a judicial or administrative body of competent jurisdiction that resulted in a judgment, decree, or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws, or finding any violation with respect to such laws, during the last five years.

Related Party Transactions

• The filing details transactions in BridgeBio Pharma Common Stock effected by various entities within the Viking Global Investors group, which are considered related parties for the purpose of this joint filing.

Stakeholder Impact

• Shareholders may react to the significant reduction in holdings by a major institutional investor, potentially leading to a negative impact on the stock price.
• The continued, albeit reduced, significant stake by Viking Global Investors may still provide some level of confidence to other investors.

Next Steps

• The Reporting Persons will continue to file amendments to Schedule 13D as required by SEC regulations if there are further material changes to their beneficial ownership or investment intent.

Key Dates

Keywords

BridgeBio Pharma, Viking Global Investors, Schedule 13D, Beneficial Ownership, Institutional Investor, Stock Transactions, SEC Filing, Biotechnology, Pharmaceuticals, Investment Management